Researchers reported in vitro activity for an EPHRIN-B2-based CAR-T cell approach against multiple brain tumor cell lines. The work included mapping of EPHA2 and EPHB4 expression across human brain tumor specimens to select targets likely to be present in tumor tissue. The preclinical findings show that CAR-T cells recognizing the EPHRIN-B2 axis can exert cytotoxic activity in laboratory models spanning six tumor lines. The study’s focus on target expression patterns in patient-derived specimens aims to strengthen the translational rationale for advancing beyond bench experiments. While results are limited to in vitro characterization, CAR-T developers frequently depend on paired target validation and early functional readouts to guide subsequent animal efficacy studies and potential clinical design.